96 related articles for article (PubMed ID: 7529428)
21. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
22. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.
Ghossein RA; Rosai J; Scher HI; Seiden M; Zhang ZF; Sun M; Chang G; Berlane K; Krithivas K; Kantoff PW
Urology; 1997 Jul; 50(1):100-5. PubMed ID: 9218026
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
25. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
26. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
27. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
29. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
30. [Prostate carcinoma (PC)--an organ-related specific pathological neoplasm].
Massmann J; Funk A; Altwein J; Praetorius M
Radiologe; 2003 Jun; 43(6):423-31. PubMed ID: 12827256
[TBL] [Abstract][Full Text] [Related]
31. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.
Eastham JA
Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622
[TBL] [Abstract][Full Text] [Related]
33. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.
Bostwick DG; Grignon DJ; Hammond ME; Amin MB; Cohen M; Crawford D; Gospadarowicz M; Kaplan RS; Miller DS; Montironi R; Pajak TF; Pollack A; Srigley JR; Yarbro JW
Arch Pathol Lab Med; 2000 Jul; 124(7):995-1000. PubMed ID: 10888774
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer grading: the NPCP system.
Gaeta JF; Asirwatham JE
Semin Urol; 1983 Aug; 1(3):193-203. PubMed ID: 6678468
[TBL] [Abstract][Full Text] [Related]
36. [An overview of new prognostic factors in lung cancer].
Karato A; Saijo N
Gan To Kagaku Ryoho; 1992 Jan; 19(1):14-9. PubMed ID: 1346085
[TBL] [Abstract][Full Text] [Related]
37. Modal DNA as prognostic indicator in untreated prostatic cancer.
Hedlund PO; Adolfsson J; Rönström L; Tribukait B
Scand J Urol Nephrol Suppl; 1988; 110():125-9. PubMed ID: 3187399
[No Abstract] [Full Text] [Related]
38. Time-dependent prognostic factors in advanced prostatic cancer.
Suciu S; Sylvester RJ; Yamanaka H
Prog Clin Biol Res; 1990; 357():203-15. PubMed ID: 2217465
[No Abstract] [Full Text] [Related]
39. Clue to metastasis in prostate cancer.
Scott WW
Geriatrics; 1971 Oct; 26(10):46. PubMed ID: 5099241
[No Abstract] [Full Text] [Related]
40. Mechanisms of metastasis: prostate cancer.
Glaves D
Prog Clin Biol Res; 1987; 239():329-45. PubMed ID: 3309960
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
